Dr. Shore’s article chosen as a NEJM “Most Notable Articles of 2020”

Neal Shore, MD, Article Featured in Notable Articles of 2020 by The New England Journal of Medicine.

The New England Journal of Medicine editors have selected Dr. Shore’s article Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer to be featured in Notable Articles of 2020. This is a selection of articles that have been the most meaningful in changing medical practice and improving patient care in 2020.

 

To access this article please click the link below for The New England Journal of Medicine’s website and create a free log-in. Once logged into your account, the collection will be accessible under the “Special Offers” tab.

Click here for the New England Journal of Medicine’s website.

Neal Shore, MD, FACS: Relugolix Approval for Advanced Prostate Cancer

Interview with Neal Shore, MD, FACS, about the approval of Relugolix for advanced prostate cancer and the significance of the treatment.

Click here to read more.

Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

Neal Shore, Steven A. Kaplan, Ronald Tutrone, Richard Levin, James Bailen, Alan Hay, Susan Kalota, Mohamed Bidair, Sheldon Freedman, Kenneth Goldberg, Frederick Snoy & Jonathan I. Epstein

Click here to read more.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al.

Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

Click here to read more.

Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer

Neal D. Shore, Alicia K. Morgans, Charles J. Ryan

Click here to read more.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, M.D., Joaquin Mateo, M.D., Karim Fizazi, M.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Antoine Thiery-Vuillemin, M.D., Przemyslaw Twardowski, M.D., et al., for the PROfound Trial Investigators*

Click here to read more.

Interview with Dr. Neal Shore Featured on WCSC Live 5 News

Prostate cancer treatment interview with Dr. Neal Shore featured on WCSC Live 5 News

Click on the video below to watch the interview:

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Marie-Aude Le Berre, M.Sc., Oana Petrenciuc, M.D., et al., for the ARAMIS Investigators*

Click here to read more.

CURC & Dr. Neal Shore Featured In USA TODAY Article On FDA Approval of Liquid Biopsy Testing

‘Coming into their own’: FDA approval of liquid biopsy tests puts early, less invasive cancer detection in broader reach

Click here to read more.